DDInter284 DDInter1676
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cannabidiol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aprepitant
Cannabidiol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Cannabidiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Cannabidiol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Cannabidiol {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cannabidiol may lead to a major life threatening interaction when taken with Teriflunomide